Compare Indoco Remedies with TIMKEN INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TIMKEN INDIA - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TIMKEN INDIA 
   Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TIMKEN INDIA INDOCO REMEDIES/
TIMKEN INDIA
 
P/E (TTM) x 73.7 34.5 213.6% View Chart
P/BV x 2.9 4.7 61.1% View Chart
Dividend Yield % 0.5 0.1 440.9%  

Financials

 INDOCO REMEDIES   TIMKEN INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
TIMKEN INDIA
Mar-19
INDOCO REMEDIES/
TIMKEN INDIA
5-Yr Chart
Click to enlarge
High Rs317812 39.1%   
Low Rs178496 35.9%   
Sales per share (Unadj.) Rs113.1221.3 51.1%  
Earnings per share (Unadj.) Rs4.519.8 22.6%  
Cash flow per share (Unadj.) Rs11.830.3 39.0%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.40.2 264.0%  
Book value per share (Unadj.) Rs73.2178.3 41.1%  
Shares outstanding (eoy) m92.1575.20 122.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.23.0 74.2%   
Avg P/E ratio x55.533.1 167.7%  
P/CF ratio (eoy) x21.021.6 97.2%  
Price / Book Value ratio x3.43.7 92.2%  
Dividend payout %22.45.1 442.5%   
Avg Mkt Cap Rs m22,83049,177 46.4%   
No. of employees `0005.51.2 445.3%   
Total wages/salary Rs m2,2091,227 180.1%   
Avg. sales/employee Rs Th1,910.113,587.2 14.1%   
Avg. wages/employee Rs Th405.01,001.6 40.4%   
Avg. net profit/employee Rs Th75.51,213.4 6.2%   
INCOME DATA
Net Sales Rs m10,41916,644 62.6%  
Other income Rs m47163 28.8%   
Total revenues Rs m10,46616,807 62.3%   
Gross profit Rs m1,3492,886 46.7%  
Depreciation Rs m677793 85.4%   
Interest Rs m23518 1,335.8%   
Profit before tax Rs m4842,238 21.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m72752 9.6%   
Profit after tax Rs m4121,486 27.7%  
Gross profit margin %12.917.3 74.7%  
Effective tax rate %15.033.6 44.5%   
Net profit margin %4.08.9 44.2%  
BALANCE SHEET DATA
Current assets Rs m5,3738,762 61.3%   
Current liabilities Rs m4,1573,103 133.9%   
Net working cap to sales %11.734.0 34.3%  
Current ratio x1.32.8 45.8%  
Inventory Days Days6870 97.4%  
Debtors Days Days7366 110.0%  
Net fixed assets Rs m6,2445,017 124.5%   
Share capital Rs m184752 24.5%   
"Free" reserves Rs m6,56612,655 51.9%   
Net worth Rs m6,75013,407 50.3%   
Long term debt Rs m1,2330-   
Total assets Rs m12,36317,757 69.6%  
Interest coverage x3.1128.2 2.4%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.9 89.9%   
Return on assets %5.28.5 61.8%  
Return on equity %6.111.1 55.0%  
Return on capital %9.016.8 53.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7623,928 95.8%   
Fx outflow Rs m1,1433,815 30.0%   
Net fx Rs m2,619113 2,317.6%   
CASH FLOW
From Operations Rs m1,2272,488 49.3%  
From Investments Rs m-1,360-1,097 123.9%  
From Financial Activity Rs m-388-233 166.4%  
Net Cashflow Rs m-5211,195 -43.6%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 5.5 227.3%  
FIIs % 6.0 6.4 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.2 169.7%  
Shareholders   12,805 49,890 25.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TATA INVESTMENT  CCL INTERNATIONAL  S.P. APPARELS  CHOLAMANDALAM INVEST.  EDELWEISS FINANCIAL  



Today's Market

Sensex Ends 416 Points Lower; Banking and Energy Stocks Witness Huge Selling(Closing)

After hitting record highs in the morning trade today, India share markets gave up all the gains and ended near day's low with Nifty below 12,250 level.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TIMKEN INDIA Announces Quarterly Results (2QFY20); Net Profit Up 44.1% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TIMKEN INDIA has posted a net profit of Rs 498 m (up 44.1% YoY). Sales on the other hand came in at Rs 4 bn (down 3.1% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

TIMKEN INDIA Announces Quarterly Results (1QFY20); Net Profit Up 59.6% (Quarterly Result Update)

Aug 16, 2019 | Updated on Aug 16, 2019

For the quarter ended June 2019, TIMKEN INDIA has posted a net profit of Rs 505 m (up 59.6% YoY). Sales on the other hand came in at Rs 4 bn (up 14.2% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TIMKEN INDIA 2018-19 Annual Report Analysis (Annual Result Update)

Jul 19, 2019 | Updated on Jul 19, 2019

Here's an analysis of the annual report of TIMKEN INDIA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TIMKEN INDIA. Also includes updates on the valuation of TIMKEN INDIA.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 20, 2020 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS